Marek Malý
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marek Malý has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Eline Op de Coul
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
2 shared publications - Jan Kynčl
Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
2 shared publications - Maria Wessman
Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
2 shared publications - Michaela Spackova
Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
2 shared publications - Monika Liptáková
Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic
2 shared publications - Ana Paula Finatto Canabarro
Department of Global Public Health, Karolinska Institutet , Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (32) , 2500921
Multi-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023
BACKGROUND: With improvements in test sensitivity and testing frequency, more people in Europe are diagnosed during the HIV acute/seroconversion phase, when their CD4 + T-cell count can be temporarily low. AIM: We piloted a revised definition of late HIV diagnosis for surveillance which considers laboratory markers, evidence of HIV test negativity in the past year and clinical evidence of recent HIV acquisition, to better distinguish between people diagnosed late and those diagnosed during the acute/seroconversion phase. METHODS: We collected pseudonymised HIV diagnosis records for 2022 and 2023 from nine European countries (Belgium, Czechia, Denmark, Germany, Greece, Italy, the Netherlands, Portugal and Sweden). We applied the revised definition to reclassify those with evidence of recently acquired HIV as 'not late' and calculated the corresponding correction factor by country and demographic group. Individuals with a previous diagnosis were excluded from the analysis. RESULTS: Among 10,220 individuals with a CD4 + T-cell count at diagnosis, 56% (5,689/10,220) had a CD4 + T-cell count < 350 cells/µL or an AIDS-defining event at diagnosis. Applying the revised definition reduced the late diagnosis proportion from 56% to 50%, a correction factor of 9% (535/5,689). The correction factor ranged between 3% and 25% across countries and was higher for younger ages and for gay, bisexual and other men who have sex with men, compared with other groups. CONCLUSIONS: Without reclassification, late HIV diagnosis proportions are overestimated. We provide recommendations and validity considerations for countries intending to use the revised definition.
- 13 August 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (32) , 2500921
Open AccessMulti-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023
BACKGROUND: With improvements in test sensitivity and testing frequency, more people in Europe are diagnosed during the HIV acute/seroconversion phase, when their CD4 + T-cell count can be temporarily low. AIM: We piloted a revised definition of late HIV diagnosis for surveillance which considers laboratory markers, evidence of HIV test negativity in the past year and clinical evidence of recent HIV acquisition, to better distinguish between people diagnosed late and those diagnosed during the acute/seroconversion phase. METHODS: We collected pseudonymised HIV diagnosis records for 2022 and 2023 from nine European countries (Belgium, Czechia, Denmark, Germany, Greece, Italy, the Netherlands, Portugal and Sweden). We applied the revised definition to reclassify those with evidence of recently acquired HIV as 'not late' and calculated the corresponding correction factor by country and demographic group. Individuals with a previous diagnosis were excluded from the analysis. RESULTS: Among 10,220 individuals with a CD4 + T-cell count at diagnosis, 56% (5,689/10,220) had a CD4 + T-cell count < 350 cells/µL or an AIDS-defining event at diagnosis. Applying the revised definition reduced the late diagnosis proportion from 56% to 50%, a correction factor of 9% (535/5,689). The correction factor ranged between 3% and 25% across countries and was higher for younger ages and for gay, bisexual and other men who have sex with men, compared with other groups. CONCLUSIONS: Without reclassification, late HIV diagnosis proportions are overestimated. We provide recommendations and validity considerations for countries intending to use the revised definition.
- Open Access
- 9 April 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Use of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.
- 9 April 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Open AccessUse of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.
- Open Access
- 25 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Measles – retrospective study of cases reported in a national notification system, Czech Republic, 2018–2024
Background: In response to the recent increase in measles cases and outbreaks across Europe, Czech surveillance data were analysed. The aim was also to evaluate the effect of vaccination on measles complications. Methods: Cases of measles reported to the national surveillance system according to the EU case definition (2018) between 2018–2024, were analysed. Demographic characteristics were assessed using descriptive analysis (counts and proportions). Logistic regression with an odds ratio (OR) supplemented with the 95% confidence interval (95% CI) was calculated to measure the association between vaccination status and the occurrence of complications. Results: A total of 791 measles cases were reported during the study period, of which 762 (96%) were laboratory confirmed, 29 (4%) were probable and 416 (53%) were male. Most cases (546; 69%) occurred in 2019. Half of the cases ( n = 395, 50%) were outbreak related. The median age of cases was 33 years (range: 0–54). In total, 109 (14%) measles cases were imported (62 from Ukraine and smaller numbers from 25 other countries; 57 of the imported cases were unvaccinated) and 523 cases (70%) were hospitalised. In total, 330 (42%) of all cases were known to have been vaccinated, of which 205 (62%) with two or three doses and 75 (23%) with only one dose. Of 88 complications (11% of all cases) was pneumonia most frequent (n = 19; 2%). The highest proportion of complications occurred in infants (< 1 year [too young to be vaccinated]; 28%) and in children aged 1–4 years (20%). Compared to unvaccinated cases, two and more vaccine doses significantly reduced odds of any complications (OR = 0.44, 95% CI: 0.24–0.81, p = 0.008). Conclusions: Within analysed 7-year period most cases were detected pre-pandemic in 2018 and 2019. It is likely that restrictive measures limited further epidemic potential. Isolation of measles case is mandatory in Czech Republic; therefore, this criterion does not reflect the clinical severity of cases. Having this limitation in mind, the effect of vaccination against measles complications only was demonstrated. To prevent further cases, increased awareness and promotion of measles vaccination is recommended for all individuals, including travellers, as a substantial proportion of cases were unvaccinated.
- 25 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessMeasles – retrospective study of cases reported in a national notification system, Czech Republic, 2018–2024
Background: In response to the recent increase in measles cases and outbreaks across Europe, Czech surveillance data were analysed. The aim was also to evaluate the effect of vaccination on measles complications. Methods: Cases of measles reported to the national surveillance system according to the EU case definition (2018) between 2018–2024, were analysed. Demographic characteristics were assessed using descriptive analysis (counts and proportions). Logistic regression with an odds ratio (OR) supplemented with the 95% confidence interval (95% CI) was calculated to measure the association between vaccination status and the occurrence of complications. Results: A total of 791 measles cases were reported during the study period, of which 762 (96%) were laboratory confirmed, 29 (4%) were probable and 416 (53%) were male. Most cases (546; 69%) occurred in 2019. Half of the cases ( n = 395, 50%) were outbreak related. The median age of cases was 33 years (range: 0–54). In total, 109 (14%) measles cases were imported (62 from Ukraine and smaller numbers from 25 other countries; 57 of the imported cases were unvaccinated) and 523 cases (70%) were hospitalised. In total, 330 (42%) of all cases were known to have been vaccinated, of which 205 (62%) with two or three doses and 75 (23%) with only one dose. Of 88 complications (11% of all cases) was pneumonia most frequent (n = 19; 2%). The highest proportion of complications occurred in infants (< 1 year [too young to be vaccinated]; 28%) and in children aged 1–4 years (20%). Compared to unvaccinated cases, two and more vaccine doses significantly reduced odds of any complications (OR = 0.44, 95% CI: 0.24–0.81, p = 0.008). Conclusions: Within analysed 7-year period most cases were detected pre-pandemic in 2018 and 2019. It is likely that restrictive measures limited further epidemic potential. Isolation of measles case is mandatory in Czech Republic; therefore, this criterion does not reflect the clinical severity of cases. Having this limitation in mind, the effect of vaccination against measles complications only was demonstrated. To prevent further cases, increased awareness and promotion of measles vaccination is recommended for all individuals, including travellers, as a substantial proportion of cases were unvaccinated.
- 23 February 2026
- Published by Springer Nature in Journal of Mountain Science
- Vol. 23 (2) , 470-488
Rime ice formation: Insight into time trends over the last two decades based on observations in a Central European country
- 23 February 2026
- Published by Springer Nature in Journal of Mountain Science
- Vol. 23 (2) , 470-488
Rime ice formation: Insight into time trends over the last two decades based on observations in a Central European country
- 1 December 2025
- Vol. 31 (4) , 142-150
[Epidemiological data on HIV/AIDS and the surveillance system in the Czech Republic].
Human immunodeficiency virus (HIV) progressively impairs immune function. If the infection is detected late or left untreated, it leads to the development of AIDS. Therefore, from a public health perspective, it is necessary to monitor the occurrence of infection in the population, as well as trends overall and in specific subgroups. This is achieved through a national HIV surveillance system, whose outputs can be used not only to describe the epidemiological situation but also to guide preventive activities. The text outlines the organizational components of the surveillance system developed since 1986 and presents the key epidemiological data describing the HIV epidemic in the Czech Republic. Between 1985 and 2024, a total of 4888 cases of HIV infection were detected among Czech citizens and foreigners with long-term or permanent residence. Of those, 926 were diagnosed with AIDS, and 654 died. The basic characteristics of the HIV epidemic in the Czech Republic are the predominance of sexual transmission, especially among men who have sex with men, but with increasing numbers of heterosexually transmitted infections, a low proportion of women (approximately 15%), and an increasing proportion of foreigners (48% in the last five years). The annual number of new cases initially hovered around a few dozen, then steadily increased from 2003 until reaching 286 in 2016. After a slight decline, the numbers peaked at 292 in 2022. Recent trends have been affected by the COVID-19 pandemic and the war in Ukraine. In addition to the above figures, 856 HIV-positive refugees from Ukraine were registered in 2022-2024. Despite these facts, the Czech Republic continues to be classified as a low-prevalence country in both the European and global contexts. However, the trend in recent years has not been favorable, with the number of new cases showing a slight increase. Keywords: HIV, AIDS, surveillance, HIV transmission, foreigners.
- 1 December 2025
- Vol. 31 (4) , 142-150
[Epidemiological data on HIV/AIDS and the surveillance system in the Czech Republic].
Human immunodeficiency virus (HIV) progressively impairs immune function. If the infection is detected late or left untreated, it leads to the development of AIDS. Therefore, from a public health perspective, it is necessary to monitor the occurrence of infection in the population, as well as trends overall and in specific subgroups. This is achieved through a national HIV surveillance system, whose outputs can be used not only to describe the epidemiological situation but also to guide preventive activities. The text outlines the organizational components of the surveillance system developed since 1986 and presents the key epidemiological data describing the HIV epidemic in the Czech Republic. Between 1985 and 2024, a total of 4888 cases of HIV infection were detected among Czech citizens and foreigners with long-term or permanent residence. Of those, 926 were diagnosed with AIDS, and 654 died. The basic characteristics of the HIV epidemic in the Czech Republic are the predominance of sexual transmission, especially among men who have sex with men, but with increasing numbers of heterosexually transmitted infections, a low proportion of women (approximately 15%), and an increasing proportion of foreigners (48% in the last five years). The annual number of new cases initially hovered around a few dozen, then steadily increased from 2003 until reaching 286 in 2016. After a slight decline, the numbers peaked at 292 in 2022. Recent trends have been affected by the COVID-19 pandemic and the war in Ukraine. In addition to the above figures, 856 HIV-positive refugees from Ukraine were registered in 2022-2024. Despite these facts, the Czech Republic continues to be classified as a low-prevalence country in both the European and global contexts. However, the trend in recent years has not been favorable, with the number of new cases showing a slight increase. Keywords: HIV, AIDS, surveillance, HIV transmission, foreigners.
- Open Access
- 23 September 2024
- Published by Walter de Gruyter GmbH in Slovenian Journal of Public Health
- Vol. 63 (4) , 205-213
Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013–2022
Introduction: Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. Methods: The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. Results: A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0–89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35–44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. Conclusions: Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.
- 23 September 2024
- Published by Walter de Gruyter GmbH in Slovenian Journal of Public Health
- Vol. 63 (4) , 205-213
Open AccessMonitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013–2022
Introduction: Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. Methods: The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. Results: A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0–89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35–44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. Conclusions: Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.